Tag: $Johnson and Johnson

Adjusted earnings per share of $2.59 beat the consensus estimate of $2.53 by $0.06. Revenue reached $25.4 billion, slightly above the $25.38 billion consensus, representing a 5.9% increase from $24.0 billion in the same quarter last year.

Drugmaker Johnson & Johnson has announced a $5.5bn agreement to end long-running US litigation involving tens of thousands of claims that talcum powder allegedly caused ovarian cancer.

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. Wall Street shrugged at the results.

Johnson & Johnson (JNJ) has reinvented itself several times in recent years. In 2021, it was best known as the developer of a Covid vaccine.

Johnson & Johnson had another strong quarter, driven by revenue growth of two important cancer drugs, but it also reported lower-than-expected net profit.

Johnson & Johnson has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration.